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Abstract 
A Comparison of the Effects of Romidepsin Treatment on Gene Expression in a 
Leukemic Patient with Sezary Syndrome Using Two Different Methods for Blood 
Collection 
Shere Shievonne Billouin 
Louise C. Showe, Ph.D. 
James R. Spotila, Ph.D. 
 
 
 
Background: Sezary Syndrome (SS), an aggressive, leukemic form of Cutaneous 
T-Cell Lymphoma, is resistant to conventional treatments with chemotherapy. 
Although SS is treated with several modalities, these therapies have poor response 
rates and are not curative. Histone Deacetylase Inhibitors (HDACi) are newer 
treatments that have been shown to be an effective treatment option for SS. 
Although the response of SS patients to HDACi has been encouraging, the 
response mechanisms are not understood. This project examined the effect of 
HDACi treatment on gene expression patterns using a novel HDACi known as 
Romidepsin. As a first step, two different blood sample collection methods were 
compared. Blood samples were collected from a SS patient using the BD 
Vacutainer(R) CPT(TM) Cell Preparation tubes that are routinely used for peripheral 
blood mononuclear cells (PBMC) isolation, and with a newer method for whole 
blood sample collection in PreAnalytiX PAXgene tubes. PAXgene tubes do not 
require PBMC purification for RNA isolation, but the RNA is immediately 
stabilized at the time of collection into the PAXgene reagent. Validation of the 
PAXgene method would standardize sample collection for blood based 
microarray studies and eliminate the need to rapidly process CPT samples to 
maintain mRNA profiles.  Previous research has shown that varying blood 
 ix 
collection methods and processing times for RNA purification significantly 
impacts steady state gene expression profiles, and affects the conclusions of these 
studies, such as a measure of the effectiveness of a treatment. 
Objectives: This research examined the effects of progressive Romidepsin 
treatment on gene expression in blood samples collected pre- and 4 hours post- 
treatment over 6 months. Samples were collected in CPT and PAXgene tubes. 
CPT tubes require rapid processing and yield only purified PBMCs for 
downstream RNA projects, whereas PAXgene tubes, which can be stored before 
processing, yield immediately stabilized RNA from mononuclear cells and 
granulocytes. Gene expression patterns from both collection systems were 
compared to determine whether the PAXgene method, which includes cell types 
lost in the PBMC purification, will yield new and important information as 
compared to the CPT method. 
Methods: Peripheral blood samples from a SS patient treated with Romidepsin 
were collected in CPT and PAXgene tubes. PBMC were purified from the CPT 
samples within 2 hours of collection. In one case, the CPT sample was processed 
24 hrs after collection.  RNA was then extracted from the PBMC samples and 
RNA was also purified from the PAXgene samples after several months of 
storage at -80oC. The RNA samples were amplified utilizing the Illumina® Total 
PrepTM RNA Amplification kit followed by hybridization to the Illumina® Sentrix 
Human Expression BeadChips for microarray analysis. Data analysis was 
performed and validation of some genes using quantitative Real Time-Polymerase 
Chain Reaction. 
 x 
Results & Conclusions:  
• CPT and PAXgene samples cluster together based on the timepoint of 
collection and not the tube type. 
• Changes in gene expression were detected over the 6 months of treatment 
in the pre-Romidepsin treatment samples taken one month apart indicating 
a cumulative effect of treatment over time. 
• The overall gene expression pattern is very similar between the two blood 
collection methods, although PAXgene tubes do recover genes from 
different cell types with varying sensitivities. 
• Samples in CPT tubes that are stored after collection at 4oC overnight and 
processed the next day yield inaccurate gene expression results. However, 
PAXgene samples that are stored at -80oC for several months after 
collection yield consistent gene expression results. 
• SS biomarkers identified in earlier published studies were validated. 
Romidepsin treatment changed the expression of these genes to levels 
relatively similar to that in a healthy donor indicating reductions in the 
level of malignant T-cells. 
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CHAPTER 1: BACKGROUND – MYCOSIS FUNGOIDES AND SEZARY 
SYNDROME 
 
Epidemiology 
The Cutaneous T-cell Lymphomas (CTCL) are a diverse group of extra-nodal 
non-Hodgkin’s lymphomas that have a wide range of distinct clinical, cytogenic, 
histopathological and immunophenotypic manifestations. These lymphomas are 
characterized by the clonal proliferation of mature, malignant, skin-invasive CD4+ helper 
T-cells. Currently, the classification system of primary cutaneous lymphomas by the 
World Health Organization – European Organization for Research and Treatment of 
Cancer (WHO-EORTC) encompasses fourteen CTCLs, which are distinguished 
according to having either an indolent or aggressive clinical behavior (Table 1), with T-
cell lymphomas representing approximately 80% of all cutaneous lymphomas (1). 
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 Table 1: WHO-EORTC classification of Cutaneous T-Cell Lymphomas.  
The CTCL subtypes can be categorized by having either an indolent or aggressive 
clinical behavior. 
Indolent Clinical Behavior Aggressive Clinical Behavior 
Mycosis Fungoides Sezary Syndrome 
Folliculotropic Mycosis Fungoides Adult T-cell Leukemia/Lymphoma 
Pagetoid Reticulosis Primary Cutaneous Peripheral T-cell 
Lymphoma, unspecified 
Granulomatous Slack Skin Primary Cutaneous Aggressive 
Epidermotropic CD8+ T-cell Lymphoma 
(provisional) 
Primary Cutaneous Anaplastic Large Cell 
Lymphoma 
Cutaneous Gamma/Delta T-cell Lymphoma 
(provisional) 
Lymphomatoid Papulosis Extranodal NK/T-cell Lymphoma, nasal type 
Subcutaneous Panniculitic like T-cell 
Lymphoma (provisional) 
 
Primary Cutaneous CD4+ Small/Medium-
sized Plemorphic T-cell Lymphoma 
(provisional) 
 
 
 
 
The CTCLs are relatively rare cancers although the incidence is increasing.  A 
total of 4,783 new cases of CTCL were identified from 1973–2002 with 72% being 
confirmed as Mycosis Fungoides (MF) and only 2.5% as Sezary Syndrome (SS) (2). 
Furthermore, MF is slightly more dominant in males as compared to females with a 2:1 
ratio (3), and has a higher prevalence among both older age groups and in the black race 
population (2). 
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Etiology 
 The etiologies of most CTCLs, including MF and SS, are still unknown. Several 
probable causative agents, including exposure to environmental factors, genetic 
predisposition and infectious agents have been studied but none of these studies have 
yielded definitive results as to the origin of MF and SS. 
 Recent studies have shown that there is a 24% to 40% decrease in the risk of non-
Hodgkin’s lymphomas upon sun exposure (4), as it is hypothesized that the production of 
Vitamin D from sun exposure may have a protective role against non-Hodgkin’s 
lymphomas, including MF and SS, with CTCL usually appearing on areas of the body 
normally protected from the sun.  
Chemical stimulation of antigens, alcohol consumption and smoking have also 
been investigated as possible causative factors for MF and SS (5-6). Additionally, 
although a positive correlation has been shown between increased alcohol consumption 
and a higher risk of MF, alcohol intake could not be considered as the sole risk factor for 
the occurrence of MF. There was also no significant effect of smoking on an increased 
MF risk. 
Familial cases of CTCL are also rare, with only 8 documented occurrences. 
Tissue typing studies for HLA antigens have not found any relationship between this 
allele and the occurrence of MF in sibling pairs (7). Additionally, a retroviral cause of 
MF has been examined, as human T-cell lymphotropic virus type 1 (HTLV-1) is known 
to be the causative agent of adult T-cell leukemia/lymphoma (ATLL), another subtype of 
CTCL. However, in situ PCR studies have shown that although the HTLV-1 Tax 
sequence is present in the peripheral blood mononuclear cells (PBMCs) of some MF 
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patients, it is also present in the PBMCs of healthy control donors, and as such HTLV-1 
cannot be regarded as the causative agent of MF (8). 
 
 
Clinical Manifestation of Cutaneous T-Cell Lymphoma 
 Classical MF is an indolent disease that typically progresses through 3 stages: 
patch, plaque and tumor. In the patch phase, patients clinically diagnosed with MF 
present with a variable number of reddened, scaly lesions lacking significant elevation 
typically on sun-shielded areas of the body such as the breasts, inner thigh, and buttocks, 
but these lesions can ultimately occur on other parts of the body (Figure 1). These lesions 
range in diameter from 2-15cm, but in some cases the diameter may exceed 15cm (9). In 
addition, patients in the patch stage may also experience severe pruritus (itching). 
 
 
 
 
Figure 1: Patch Stage of Mycosis Fungoides 
The patch is located on the proximal arm (adapted from (10)) 
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In some instances, patients with early stage MF are misdiagnosed with other 
inflammatory dermatological conditions, such as psoriasis, chronic eczema or atopic 
dermatitis, as a result of the similarity in non-specific scaly lesions covering the body.  
Specifically, MF has a false positive diagnosis rate of 44% and a false negative rate of 
40% (11). Usually, a histological diagnosis is confirmed at the late patch or the early 
plaque stages of MF. 
 Typically, it takes several years for a patient to progress from the early patch 
stage of MF to the plaque and subsequent tumor stages. Research by Kamarashev, J. et. 
al. reviewed 48 MF patients and showed that that there is an average duration of 7.2 years 
in the patch stage, 2.3 years in the plaque stage, and 1.8 years in the tumor stage (12). 
Moreover, some of these patients also further progressed to develop lymph node 
infiltration and later multiple organ infiltration. However, some patients can remain in the 
patch stage for decades without progression to the plaque or tumor stages. The reasons 
for these differences are not known. 
 In the plaque stage, the scaly lesions gain significant elevation and may join 
together with neighboring plaques to form larger plaques (Figure 2). Some patients may 
also progress to the tumor stage where the plaques become ulcerated  
Figure 3). The growth of tumors indicates a greater migration of malignant helper T-cells 
into the skin. 
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Figure 2: Plaque Stage of Mycosis Fungoides 
The plaques are located near the underarm (adapted from (10)) 
 
 
 
 
 
Figure 3: Tumor Stage of Mycosis Fungoides 
The tumor is located on the arm (adapted from (13)) 
 
 
 
 Additionally, some MF patients may progress to develop SS, which is an 
aggressive, leukemic form of CTCL that is characterized by acute pruritus and 
erythroderma on >80% of the body (Figure 4). SS can also occur de novo without any 
previous presentation with MF. 
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Figure 4: Sezary Syndrome 
This patient has >80% erythematous lesions covering the body (adapted from (10)) 
  
 
 
SS is correlated with the presence of malignant lymphocytes having cerebriform 
nuclei known as Sezary cells circulating in the peripheral blood (Figure 5). Similar 
atypical cells account for ~5% of the normal total lymphocyte count (14) but they can 
reach as high as 99% in advanced SS cases.  
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Figure 5: Sezary cell showing the convoluted nuclei with a prominent nucleolus 
(adapted from (15)) 
 
 
 
In addition, SS is also defined by an absolute Sezary cell count of ≥1000 
cells/mm3 and a CD4/CD8 ratio equivalent to ≥10, along with the occurrence of 
lymphadenopathy. However, in healthy individuals, a CD4/CD8 ratio range of 0.6 – 5.0 
has been defined in peripheral blood (16). Additionally, patients diagnosed with SS have 
an average survival rate of 2 to 4 years (17). 
  
Staging of Cutaneous T-cell Lymphoma 
 MF and SS are categorized according to a tumor-node-metastasis-blood (TNMB) 
classification staging system, which was developed by the National Cancer Institute 
(NCI) and recently modified to include peripheral blood involvement by the International 
Society for Cutaneous Lymphoma (Table 2). The TNMB classification system accounts 
for skin involvement, as well as the occurrence of lymph node or visceral disease, and the 
presence of Sezary cells in the peripheral blood (18).   
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Table 2: Tumor-node-metastasis-blood (TNMB) classification system for Mycosis 
Fungoides and Sezary Syndrome 
(adapted from (13)) 
Stage Definition 
T1 Patch/plaque, or both on <10% of body surface area 
T2 Patch/plaque, or both on >10% of body surface area 
T3 Cutaneous tumors 
T4 Erythroderma 
N0 Lymph nodes clinically uninvolved 
N1 Lymph nodes clinically abnormal but not histologically involved 
N2 Lymph nodes clinically nonpalpable but histologically involved 
N3 Lymph nodes clinically abnormal and histologically involved 
M0 No visceral involvement 
M2 Visceral involvement 
B0 No circulating atypical Sezary cells 
B1 Circulating atypical Sezary cells 
 
 
 
 Based on the TNMB system, an overall CTCL stage may be determined ranging 
from IA to IVB utilizing the staging system from the Mycosis Fungoides Cooperative 
Group (19) (Table 3). Stages IA to IIA are classified as clinically early MF; stages IIB to 
IV are clinically advanced MF; and stages III to IV where there is significant peripheral 
blood involvement are SS (20). 
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Table 3: Clinical classification system for Mycosis Fungoides and Sezary Syndrome 
(adapted from (13)) 
Clinical Stage Skin Lymph Node Viscera 
IA T1 N0 M0 
IB T2 N0 M0 
IIA T1-2 N1 M0 
IIB T3 N0-1 M0 
IIIA T4 N0 M0 
IIIB T4 N1 M0 
IVA T1-4 N2-3 M0  
IVB T1-4 N0-3 M1 
 
 
 
Pathophsyiology and Disease Progression 
 In healthy individuals who sustain a skin injury or infection, mature memory 
CD4+ helper T-cells are recruited to the site of the injury or infection. Keratinocytes, the 
major skin cells, release cytokines in an attempt to mediate inflammatory and immune 
responses upon damage to the skin. As such, an innate immune response is elicited where 
immune cells in the skin, including dendritic cells and macrophages are activated. 
 The occurrence of this innate immune response results in the migration of 
activated antigen presenting cells (APCs) to the draining lymph nodes of the skin. In the 
lymph nodes, the APCs and complementary naïve T-cells interact resulting in an adaptive 
immune response. A portion of these naïve T-cells are stimulated to become antigen 
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specific memory T-cells, which circulate within the lymph nodes and provide long-
standing specific immune protection. 
 In CTCL, the antigen specific memory T-cells in the skin express cutaneous 
lymphocyte antigen (CLA), which is a T-cell ligand involved in the migration of memory 
T-cells to inflammatory sites in the skin. CLA interacts with E-selectin, a cell-adhesion 
molecule expressed on the endothelial cells of cutaneous venules, and mediates the 
adhesion of CLA+ memory T-cells to cytokine-activated endothelial cells. As the immune 
response progresses, chemokines released by keratinocytes enter the blood vessels and 
activate CLA+ memory T-cells, which are now able to enter the dermis and epidermis.  
 Moreover, CLA+ memory T-cells co-express Chemokine (C-C motif) Receptor 4 
(CCR4), which is a skin-homing receptor. Recent studies (21-22) provide evidence that 
CLA+ memory T-cells also co-express CCR10, which may also play a role in the 
migration of malignant T-cells into the skin. In early stage MF, CCR4, Chemokine (C-X-
C motif) Receptor 3 (CXCR3) and CXCR4 are highly expressed (23). However, as the 
disease progresses, tumor cells have a reduced expression of CCR4 and CXCR3, but an 
increased expression of CCR7, a chemokine receptor necessary for the entry of T-cells 
into lymphatic tissue (24). Additionally, the malignant CD4+ T-cells have reduced 
expression levels of specific T-cell surface makers including CD7 and CD26 (25) and 
increased expression levels of CD158k (26).  
 In MF & SS there is a migration and abnormal proliferation of these malignant 
CD4+ helper T-cells into the epidermis with clusters around and in contact with 
Langerhans cells, which are immature dendritic cells in the skin, forming Pautrier 
microabscesses that are a hallmark feature of MF and SS (Figure 6).  
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Figure 6: Pautrier microabscesses 
Skin biopsy specimen showing the atypical lymphocytes infiltrating the epidermis and 
surrounding Langerhan cells (adapted from (13)). 
 
 
 
However, the factors that initiate the constitutive activation and proliferation of 
malignant, skin-invasive CD4+ helper T-cells in MF and SS are still largely unknown. 
Recent research by C.L. Berger and colleagues provides evidence of the in vitro 
stimulation of the clonal proliferation of CTCL cells when co-cultured with immature 
dendritic cells (27). This indicates that Langerhans cells may play a direct role in the 
growth of CTCL cells in vivo. 
 In addition, CTCL undergoes a shift from a T-helper 1 (Th1) cytokine phenotype 
at early disease stages to a T-helper 2 (Th2) cytokine phenotype at advanced stages 
(Figure 7). In a study, cytokine specific monoclonal antibodies were utilized to detect 
cytokines synthesized in 12 MF patients versus 13 SS patients (28). The results showed 
that in the early stages of MF, the disease mainly displays a Th1 cytokine phenotype with 
the production of interleukin-2 (IL-2), and gamma interferon (IFN-γ). However, as the 
disease progresses to SS, a shift to a Th2 cytokine phenotype occurs with the production 
of IL-4. CD7+ was the main T-cell producing IL-2 in MF whereas in SS, it was CD7- and 
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there were also a significantly higher number of CD8+ IL-4 producing T-cells in MF as 
compared to SS or healthy control donors. Therefore, the increased synthesis of 
immunosuppressive cytokines, such as IL-4, can be potential predictors of advanced 
CTCL, as well as represent a mechanism by which the tumor cells avoid the immune 
response. 
 Other research has shown an increase in IL-10 (29), IL-15 and IL-16 (30), and IL-
17 (31) mRNA expression with the progression of MF to a tumor stage, and therefore, 
these pro-inflammatory cytokines may function as growth factors for malignant T-cells. 
In addition, research by A. Rook and colleagues has also shown that a decline in IL-12 
production is correlated to a decline in dendritic cell populations in the peripheral blood 
of SS patients (32-35). This decline in IL-12 production is also associated with reduced 
Th1 responses and diminished IFN-γ production. 
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Figure 7: Disease progression in Mycosis Fungoides and Sezary Syndrome 
Panel A shows healthy skin with Langerhan cells and T-cells in dermis and circulation. 
Panel B shows patch and plaque MF stages with atypical CD4+ Th cells infiltrating the 
epidermis and forming Pautrier microabscesses and an initial change from a Th1 to a Th2 
cytokine phenotype. There is also an increase in CD8+ cells in the dermis and epidermis 
as a function of the immune response. Panel C shows the tumor stage of MF with the 
development of a cutaneous tumor along with the clonal proliferation of atypical CD4+ 
Th cells; reduced numbers of CD8+ cells; and a greater production of Th2 cytokines. 
Panel D shows the development of erythroderma and Sezary Syndrome with atypical 
CD4+ Th cells circulating in the peripheral blood along with the continued production of 
Th2 cytokines (adapted from (13)). 
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 Furthermore, M. Wysocka and colleagues have shown a significant decrease in 
the number and activity of Natural Killer (NK) cells in advanced stages of MF/SS (36). 
This is also accompanied by a decrease in the number of CD8+ T-cells in advanced 
CTCL. This decrease in NK and CD8+ T-cell populations is associated with a 
progressively failing host immune system as a result of disease progression. 
 Other immune abnormalities associated with MF and SS include the development 
of eosinophilia at advanced stages of the disease (37); elevated levels of immunoglobulin 
A (IgA), E (IgE), and M (IgM), with IgA levels being the highest at advanced stages of 
MF and SS (38); and reduced T-cell responses to antigens. Advancing disease is 
associated with increasing immuno-supression. 
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CHAPTER 2: CTCL TREATMENTS 
 
Current Treatments 
Skin-directed and systemic therapies are currently available for the treatment of 
MF & SS, depending on the disease stage. In early stage MF, characterized by the 
formation of patches or plaques, skin-directed therapies that result in tumor cell apoptosis 
are utilized. These include phototherapy, topical corticosteroids, topical chemotherapy, 
topical retinoids, and electron beam therapy (radiation). In advanced stages of MF and 
SS, systemic therapies, including photopheresis and interferon-α (IFN-α) are employed 
(39). However, at advanced stages of CTCL, these treatments only provide a palliative 
effect. Additionally, patients usually experience recurrent CTCL and therefore, repeat 
treatments must be administered. As such, new and more effective therapies to treat 
CTCL are needed. 
 
Histone Deacetylase Inhibitors (HDACi) 
An array of investigational treatments is currently being studied to target specific 
pathways in the pathogenesis of CTCL in an attempt to enhance the host immune 
response. In particular, histone deacetylase inhibitors (HDACi) are a novel class of 
compounds that are in clinical trials to study their efficacy in the treatment of CTCL, as 
well as other cancers. 
Deregulation of gene expression by a number of different pathways has been 
attributed to the pathogenesis of several cancers, including CTCL. Histones play an 
important role in this regulation by controlling chromatin structure. There are 4 core 
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histone proteins, H2A, H2B, H3 and H4, with two copies of each histone assembling into 
an octameric nucleosome. The nucleosome is further compacted into a higher order 
structure by the linker histone H1. 
These histone proteins also have long tails protruding from the nucleosome that 
can undergo post-translational modifications, such as acetylation and deacetylation. 
These modifications, which are controlled by the activity of histone acetylases (HAT) 
and histone deacetylases (HDAC), alter the interaction between the histones and DNA 
(Figure 8).  
 
 
 
 
Figure 8: Acetylation sites on histones 
This schematic drawing illustrates the histone octamer and histone tails with the various 
post-translational modification sites, including acetylation sites (adapted from (40)). 
 
 
 
HATs acetylate the lysine residues on core histone proteins and HDACs remove 
the acetyl groups from these lysine residues. In the case of HDACi, these enzymes inhibit 
the activity of histone deacetylases. In the presence of an HDACi, the lysine residues on 
the core histone proteins become hyperacetylated, which results in the neutralization of 
the positive charges on the lysine residues. This neutralization results in a reduced 
interaction between the core histone proteins and the negatively charged phosphate 
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groups of DNA. As a result, the chromatin structure becomes less compacted, which 
enables transcription factors to access and regulate the transcription of genes. This 
promotes the expression of genes associated with apoptosis, cell differentiation and the 
suppression of cell proliferation by the activation of cell cycle checkpoints at G1/S or 
G2/M and the expression of tumor suppressor genes(41) (Figure 9). 
 
 
 
  
Histone Acetylation    
HDACi
INCREASES:
- Cell Cycle Inhibitors: p21
- Death Receptors and ligands
- Pro-apoptotic factors
- Reactive oxygen species (ROS)
- Autophagic cell death & Mitotic cell 
death
DECREASES:
- Cyclins
- Anti-apoptotic factors
- CXCR4
- c-Myc
 
Figure 9:  The downstream effects of Histone Deacetylase Inhibitors 
HDAC inhibition results in an increase in histone acetylation. This in turn promotes 
various downstream effects such as chromatin remodeling, tumor suppressor gene 
transcription, cell growth inhibition, and apoptosis. 
 
 
 
Vorinostat or suberoylanilide hydroxamic acid (SAHA) acquired by Merck & Co. 
Inc. was the first oral HDACi approved by the Food and Drug Administration (FDA) in 
October 2006 for the treatment of CTCL in patients that failed two systemic therapies. 
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Vorinostat inhibits the activity of HDACs by binding to a zinc ion in the catalytic domain 
of the enzyme, thereby inhibiting deacetylation (42). In two phase II clinical trials, 107 
patients were administered Vorinostat daily with an overall response rate of 24-30% (43). 
 
Romidespin 
Other HDACi have been in clinical trials to study their efficacy in the treatment of 
CTCL. Romidepsin, formerly known as depsipeptide or FK228 (Gloucester 
Pharmaceuticals) and studied in a multi-center phase II clinical trial was approved on 
November 5th, 2009 by the FDA for the treatment of CTCL in patients who received at 
least one prior treatment and is currently being marketed under the name Istodax..  
Romidepsin is a naturally occurring bicyclic peptide isolated from the bacterium 
Chromobacterium violaceum, which has a structure that is different from that of 
hydroxamic acids, such as Vorinostat. This difference in structure may account for the 
reason that Romidepsin is a more selective inhibitor. In addition, Romidepsin is a pro-
drug, with the active site being a sulfhydryl group that functions as a Zn2+ chelator (44).  
Previous studies have shown Romidepsin to have potent anti-tumor activity both 
in vitro and in vivo. More specifically, in vitro studies have shown Romidepsin to induce 
hyperacetylation, cell cycle arrest and cell death in various cancer cell lines, including 
chronic lymphocytic leukemia (CLL) cells (45), lung carcinoma cells (46), and leukemic 
monocyte lymphoma cells (47). In vitro studies utilizing the human T-cell lymphoma cell 
line HUT78 have also shown that Romidepsin effectively induced hyperacetylation, 
induction of p21 expression and apoptosis (48). 
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 In addition, in a Phase I clinical trial at NCI,  3 CTCL patients (2 diagnosed with 
SS and 1 with tumor-stage CTCL) were treated with Romidepsin and a partial response to 
the treatment was noted that involved a decrease in circulating Sezary cells, an 
improvement in skin erythroderma as well as an increase in hyperacetylated  Sezary cells 
(49). In a subsequent Phase II single arm, multi-center trial, 14mg/m2 of Romidepsin was 
administered for the treatment of refractory CTCL in patients ranging from stages IB to 
IVA. An overall response rate of 42% was observed in 72 evaluable patients, with 6 
patients having a clinically complete response (CCR), with an average response time of 
1.9 months (50). 
Therefore, these in vitro and in vivo studies indicate that Romidepsin is an 
effective treatment for CTCL although the mechanism for response is not known. 
However, in order to perform gene expression studies to further investigate the efficacy 
of Romidepsin, the blood collection methods used to collect samples from patients should 
be standardized for downstream assays.  
 Since CTCL and other lymphoid malignancies that respond to HDACis are 
relatively rare cancers, it is necessary to involve multiple clinical test sites where samples 
are collected to recruit enough patients for comprehensive studies.  However, it is well 
known that lymphoid cells (and other cell types) change their expression profiles 
dramatically as a function of the time from sample collection to PBMC purification and 
RNA extraction.  In order to determine whether blood collection in RNA stabilization 
tubes, such as PAXgene tubes, can be used effectively and reproducibly to study gene 
expression profiles in peripheral blood samples collected in a clinical setting, this project 
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compared gene expression profiles of matched samples acquired using the conventional 
CPT method and PAXgene method. 
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CHAPTER 3: SAMPLE COLLECTION: PAXGENE TUBES VERSUS 
VACUTAINER CELL PREPARATION TUBES 
 
 
 
Many gene expression studies are performed utilizing leukocytes isolated from 
blood samples from various pathological conditions such as non-small-cell lung cancer 
(51) and HIV (52) as well as to detect response to therapy. However, the process of 
collecting, handling, storing and transporting blood samples can result in changes in the 
relative levels of different RNAs (53-54). As such, in order to achieve consistent and 
accurate results in downstream assays, it is necessary to implement highly controlled 
protocols for collecting and processing blood samples that will preserve the gene 
expression profile of the blood samples at the time of sample collection. Since in many 
instances the equipment and expertise to isolate RNA from blood samples in a timely 
manner are not available in a clinical setting, a blood collection system that immediately 
stabilizes the RNA for later processing would be ideal for these types of situation.    
For the purpose of this research, peripheral blood samples were collected in the 
conventional BD Vacutainer® Cell Preparation tubes (CPT) for the isolation of 
peripheral blood mononuclear cells (PBMC) as well as in PreAnalytiX PAXgene tubes 
(PAX) for the direct isolation of stabilized, purified RNA.   
 The CPT tube combines a sodium citrate anticoagulant with a FICOLL™ 
HYPAQUE™ density fluid and a polyester gel barrier, which separates the anticoagulant 
from the density fluid (Figure 10). These tubes allow the collection of up to 8ml of blood, 
which must then be centrifuged within 2 hours of blood collection for the isolation of 
PBMCs. However, in most clinical settings, centrifugation instruments are frequently not 
available for this process and blood samples must be shipped to another location for 
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processing. Following the isolation of PBMCs from CPT blood samples, the RNA is 
isolated from the PBMCs for gene expression studies.  
 
 
 
 
Figure 10: BD Vacutainer® Cell Preparation tubes (CPT) 
Upon blood collection, the sample is layered onto the polyester gel. After centrifugation, 
the blood components separate based on density with PBMCs in a whitish layer under the 
plasma layer. The PBMCs must undergo an additional assay to isolate RNA (adapted 
from (55)) 
 
 
 
However, the requirement that these CPT samples be processed immediately after 
collection to retain in vivo RNA profiles compromises their use in multi-center studies 
where samples need to be transported over long distances prior to being processed. In 
addition, studies by S. Debey et. al. showed the development of a hypoxia-associated 
gene signature in PBMC samples that are not processed immediately after blood 
collection (56). This can result in inaccurate gene expression profiles from these blood 
samples.  
Unlike the CPT blood collection method, PAX tubes require the collection of only 
2.5ml of blood samples that can be frozen upon collection for several months before 
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being processed. In addition, PAX tubes contain a proprietary reagent that immediately 
stabilizes intracellular RNA in the blood samples in order to retain the in vivo RNA 
profiles, which is necessary for multi-centre studies where blood samples have to be 
transported prior to processing (Figure 11). These tubes enable the isolation of stabilized 
RNA in a single assay (mRNA and large rRNA species) that retains the gene expression 
profile at the time of blood collection (57). Although the PAX system rapidly stabilizes 
RNA profiles, the goal of this project was to compare the gene expression profiles from 
whole blood RNA extracts to the gene expression profiles from purified PBMC samples, 
which has been routinely used for earlier gene expression studies. 
 
 
 
 
Figure 11: PreAnalytiX PAXgene Blood RNA system 
These tubes contain a proprietary reagent that stabilizes intracellular RNA and enables 
the isolation of RNA in a single assay (adapted from (58)) 
  
 
 
Thus, in comparison to CPT tubes, PAX tubes require the collection of smaller 
volumes of blood; enable the storage of samples for transporting before processing; 
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immediately stabilize the cellular RNA to retain the gene expression profile to prevent 
post-phlebotomy changes; enable the direct isolation of stabilized RNA in a single assay; 
and standardize the isolation protocol across different labs which allows for consistent 
and replicable results. One of the problems with PAXgene derived RNA in the past has 
been the high levels of contamination with globin gene RNA that interferes with gene 
expression analyses.  This problem has been eliminated with the use of Illumina gene 
expression arrays. 
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CHAPTER 4: ILLUMINA MICROARRAYS: WHOLE GENOME EXPRESSION 
 
 The Illumina platform is a bead-based oligonucleotide microarray that enables 
genome-wide expression profiling of peripheral blood samples. The Illumina Sentrix 
human ref-8 version 2.0 Beadchip provides 8 arrays on each slide and examines over 
18,000 well-annotated genes using 24,136 probes. There is an average 30-fold 
redundancy for each sequence on the array, which increases the accuracy of the results. 
The oligos that are covalently attached to the beads on the chip have a 29-base address 
which is joined to a 50-base gene-specific probe. This address is used to map and decode 
the array while the gene-specific probe is used to quantify expression levels of RNA 
transcripts (Figure 12).  
 
 
 
 
Figure 12: Illumina BeadChip Design 
50-base gene-specific probes are attached to a 29-base address sequence. The address 
sequence is attached to the bead, which cover the surface of the beadchip. This diagram 
only shows one oligo attached to the bead, but actual beads have hundred of thousands of 
oligos attached to them (adapted from (59)) 
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 Research by Debey et al (60) has shown that RNA isolated from PAX tubes from 
healthy donors had gene expression profiles that were comparable on both the Affymetrix 
U133A arrays and the Illumina Beadchip platform with the Affymetrix array examining 
only 12,846 well-annotated genes using 22,215 probes. The RNA samples were treated 
with a globin-reduction procedure prior to being run on the Affymetrix and Illumina 
arrays to reduce the high levels of globin mRNAs, which are normally associated with 
PAX isolated samples, and which interfere with the hybridizations. The globin reduction 
procedures are not very reproducible and result in significant loss of RNA and 
degradation. However, recent research using the Illumina BeadChip arrays has shown 
that although globin reduction procedures applied to RNA isolated from PAX tubes 
reduces globin message levels, the globin reduction does not result in a significant 
difference in gene expression patterns as compared to RNA isolated from PAX tubes 
from the same donor that was not globin-depleted (61).  
 Although the latter studies were limited in scope, they suggested that RNA 
isolated from PAX tubes that have not been globin-depleted can be assessed for gene 
expression patterns on Illumina BeadChip arrays to ask clinically important questions.  
This would significantly reduce costs and the time required for sample preparation, allow 
for more consistent sample collection and perhaps provide important additional 
information present in the cells that are excluded by the CPT sample collection 
procedure, such as neutrophils and granulocytes. 
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CHAPTER 5: PROPOSED STUDY 
Rationale 
 The goal of this study was to use Illumina microarrays to assess global gene 
expression patterns in CPT and PAX samples collected simultaneously in a clinical 
setting. These samples were collected from a SS patient being treated with a HDACi 
known as Romidepsin. Previous studies have shown that Romidepsin treatment results in 
a significant improvement in CTCL symptoms in SS patients. The particular SS patient 
evaluated in this project was assessed as having a complete response to Romidepsin at the 
clinical level, which suggests that an altered gene expression signature related to that 
response would be detected utilizing the Illumina microarrays. Previous preliminary 
studies have shown that gene expression changes as a result of treatment could be 
detected in samples collected in CPT tubes. The goal of this project was to extend these 
studies to determine whether PAX samples could also be used to monitor response to 
therapy and to compare the gene expression results detected in the two sample types. 
Therefore, a comparison utilizing whole blood samples collected at the same time in both 
CPT and PAX tubes was performed. 
 
Hypotheses 
The specific hypotheses to be tested were (i) a SS patient treated with Romidespin will 
exhibit a response to therapy that can be examined at the gene level utilizing Illumina 
microarrays; (ii) whole blood samples collected in CPT and PAX tubes will be very 
similar in the gene expression patterns detected with Illumina microarrays (iii); and some 
differences in gene expression will be detected between the two blood collection methods 
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that may prove to be informative. These hypotheses are based on previous research by 
other groups that show (a) treatment with depsipeptide (former name for Romidepsin) 
results in alterations in gene expression patterns in the Hut78 cutaneous T-cell lymphoma 
cell lines (48) (b) treatment with Romidepsin in MF and SS patients results in a rapid 
improvement in CTCL symptoms in a subset of patients and (c) RNA isolated from 
PMBCs from CPT tubes and RNA from PAX tubes may have some differences in gene 
expression profiles owing to the mode of collection and the different types of cells 
included in the RNA extraction processes.  
 
Specific Aims 
The main goal of this project was to compare the gene expression results attained 
from samples collected in CPT and PAX tubes to determine whether the PAX tube 
collection method can replace the PBMC isolation method from CPT tubes, which is 
more difficult to standardize among different collection centers. 
An additional aim of this project was to identify genes associated with response to 
therapy using both CPT and PAX sample preparations in order to compare both methods. 
These comparisons can be used to identify biomarkers that may define gene expression 
patterns associated with response to Romidepsin treatment in a SS patient. 
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CHAPTER 6: METHODS 
 
Sample Collection 
 
SS Patient: Blood samples were collected under IRB approval and with informed consent 
of the SS patient. Samples were deidentified at the Hospital of the University of 
Pennsylvania upon collection and taken to the Wistar Institute for processing. 
 The SS patient (ID number: 4510) was a Female, Ex-smoker, Caucasian, aged 51 years 
at the start of the clinical trial and diagnosed with stage IVA SS. The patient received 
several prior treatments that were not effective.  These included Accutane, PUVA, 
Targretin, Extracorporal Photopheresis, PegIntron, Actimmune, Nitrogen Mustard and 
Topical Steroids. 
 Romidepsin was administered in a dose of 14 mg/m2 intravenously over 4 hour 
infusions on day 1 of week 1, day 8 of week 2, and day 15 of week 3 in a 28 day cycle for 
6 monthly cycles and 5 ml of peripheral blood samples were collected in BD Vacutainer® 
CPT™ tubes immediately before the start of the Romidepsin infusion (pre-treatment) and 
at the end of the 4-hour infusion (post-treatment) on weeks 1, 2 and 3 of each monthly 
cycle.  In addition, 2.5 ml of peripheral blood samples were collected in PreAnalytix 
PAXgene tubes pre-and post-treatment only on week 2 of each cycle (Figure 13). 
PAXgene samples were collected only on week 2 of each cycle to limit the amount of 
blood taken from the SS patient based on IRB requirements. As stated, the SS patient had 
a complete response to Romidepsin after 6 cycles, based on the clinical review.  
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1 Month Cycle - 
Blood Collected Pre- & 
Post- 4hr Infusion with 
Romidepsin 
Week 1 (Day 1): 
5ml in CPT Vacutainer tubes
Week 2 (Day 8): 
5ml in CPT Vacutainer tubes & 
2.5ml in Paxgene tubes
Week 3 (Day 15): 
5ml in CPT Vacutainer tubes
 
Figure 13: Blood collection schedule from the SS patient (ID number: 4510) 
Samples were collected over a total of 6 monthly cycles.  
 
 
 
Healthy Control Donor: Blood samples were collected under IRB approval and with 
informed consent of the healthy control donor (ID number: 31) at the Wistar Institute. 
The donor was a Female, Ex-smoker, Caucasian, and aged 45 years at the time of blood 
collection. Blood samples were collected on a total of 5 days over a 2-month period. 
Specifically, 5 ml of peripheral blood samples were collected in BD Vacutainer® CPT™ 
tubes and 2.5 ml were collected in PreAnalytix PAXgene tubes both in the morning (AM) 
and 4 hours later in the afternoon (PM) to mimic the blood collection schedule of the SS 
patient. Unlike the SS patient, blood samples were collected in PAX tubes at every 
collection time (Figure 14). 
 
 
 
Blood Collected In the 
Morning & 4hrs Later In 
The Afternoon
5ml in CPT Vacutainer tubes & 
2.5ml in Paxgene tubes
 
Figure 14: Blood collection schedule from the Healthy Control Donor (ID number: 31)  
Samples were collected on a total of 5 days over a 2-month period. 
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Isolation of PBMCs, RNA and cRNA synthesis 
 
Briefly, immediately after collection of blood samples in CPT tubes, the tubes 
were spun at 3100 rpm for 30 mins in a horizontal rotor (swing-out head) at room 
temperature.  After centrifugation, the PBMC layer, under the plasma layer, was aspirated 
and transferred into a 15 ml conical centrifuge tube. The cell layer underwent two similar 
wash steps: Phosphate buffered saline (PBS) was added to the conical centrifuge tube to 
bring the volume to 15 ml and the cells were mixed by inversion. The tube was 
centrifuged at 1300 rpm for 15 mins in a horizontal rotor (swing-out head) at room 
temperature. The supernatant was aspirated without disturbing the cell pellet and 
discarded. The cell pellet was then washed a second time in PBS. Following the second 
wash, the supernatant was aspirated and the cell pellet was stored in Tri-Reagent and 
RNA was purified from the cell pellet according to the manufacturer’s instructions 
(Molecular Research). 
 Unlike CPT tubes, PAX tubes contain a stabilizing additive that stabilizes 
intracellular RNA for several months and these tubes allow for the direct isolation of 
RNA from whole blood samples. The RNA was isolated from blood samples collected in 
PreAnalytix PAXgene tubes according to the manufacturer’s instructions (QIAGEN, 
Hilden, Germany). 
The RNA purified from blood samples collected in both CPT and PAX tubes was 
controlled for purity using the NanodropTM 1000 Spectrophotometer to measure the 
260/280 ratio as well as to the determine the concentration of the sample in ng/ul. 
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Next, 400 ng of total RNA was then used to synthesize cDNA followed by in 
vitro transcription to synthesize cRNA using the Illumina® TotalPrep™ RNA 
Amplification Kit as per the manufacturer’s instructions (Illumina Inc., San Diego, CA). 
The cRNA was also controlled for purity using the NanodropTM 1000 Spectrophotometer 
as well as to determine the concentration of the sample in ng/ul.  
 
Microarray profiling  using Illumina Sentrix Human Expression BeadChips 
Microarray hybridization utilizing 750 ng of cRNA and scanning of Illumina 
Sentrix Human-8 v2.0 Expression BeadChips was performed according to the 
manufacturer’s instructions (Illumina Inc., San Diego, CA) 
 
Data Normalization 
 Microarray statistical analysis was performed with the assistance of Andrew 
Kossenkov, Ph.D. A comparison of cRNA produced from blood samples collected from 
the SS patient and the healthy control donor in CPT and PAX tubes was done by 
assessing similarities and differences in gene expression levels to determine the effect of 
the blood collection method on differential gene expression utilizing the Illumina 
microarray platform. Gene expression levels were also compared in pre- and post-
Romidepsin treatment samples to identify genes associated with response to therapy. 
 Illumina BeadStudio v.3.0 software was used to export expression levels and 
detection p-values for each probe of each sample. Arrays were quantile normalized 
between each other and filtered to remove non-informative probes. A probe was called 
non-informative if it had detection p-value >0.05 in all samples or if the maximum ratio 
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between expression values was not at least 1.2 between at least two samples. 
 
Data was filtered for highly changed genes using fold change. Genes with fold 
changes above 2 between maximum and minimum expression across samples were 
extracted for further analyses. 
Fold change analysis 
 
Principal component analysis 
Matlab 7.0 functions were used to carry out principal component analysis based 
on highly changed genes. 
 
 Database for Annotation, Visualization and Integrated Discovery (DAVID, 
Functional enrichment analysis using DAVID 
http://david.abcc.ncifcrf.gov) software was used to perform function enrichment analysis 
of gene lists of interest. False discovery rate of 5% was used as a cutoff for significance.  
 
Ingenuity Pathway Analysis 
 The informative genes were subjected to post-analysis using Ingenuity Core 
Analysis (IPA 6.0, Ingenuity® Systems) (http://www.ingenuity.com/), with Benjamini-
Hochberg multiple testing corrected p-value<0.05 as a significance threshold in order to 
determine the main biologic pathways associated with Romidepsin treatment in a Sezary 
Syndrome patient. The accession number and p-values of the genes were uploaded into 
the Ingenuity software (www.ingenuity.com) to perform analyses utilizing the Ingenuity 
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Pathway Knowledge Base, which is a database created from data mining for expression 
and functional relationships extracted from published peer reviewed papers.  
 
Validation Using Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Genes with large expression differences were then selected for validation using 
qRT-PCR. Briefly, 0.25 ug of total RNA was DNase 1 (Invitrogen, Inc.) treated to 
eliminate DNA and prevent the amplification of genomic DNA in the qPCR reaction. On 
ice, 0.6 ul of 10X DNase 1 Reaction Buffer, and 1 ul of DNase 1 were added to the total 
RNA and the total reaction volume was brought to 6 ul with nuclease free water. The 
reaction mixture was heated for 15 minutes at 37oC.  To inactivate the DNase I, 1µl of 25 
mM EDTA solution was added to the reaction mixture and heated for 15 minutes at 
65°C. 
The DNA for PCR amplification was then prepared from the DNase 1 treated 
total RNA using Superscript II Reverse Transcriptase. 1 ul (250 ng) of random hexamers 
and 1 ul of 10 mM dNTP mix were added to the RNA. The reaction mixture was heated 
for 5 minutes at 65°C and then placed on ice. Next, 4 ul of 5X first strand buffer, 2 ul of 
0.1M DTT, 1 ul of RNasin and 1 ul of Superscript II Reverse Transcriptase were added to 
the reaction mixture. The mixture was incubated for 2 minutes at 25°C, 60 minutes at 
42°C and 15 minutes at 70°C and then placed on ice. Finally, 40 ul of nuclease-free water 
was then added. 
Each PCR reaction was performed using 2ul of cDNA, 5ul of Power Sybr® Green 
(Applied Biosystems Inc.), 0.05 ul each of forward and reverse gene-specific primers, and 
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the total reaction volume was brought to 10 ul with nuclease free water. The primers used 
were: 
• GATA3: 5’ TATCCATCGCGTTTAGGC forward primer and 3’ 
CCCAAGAACAGCTCGTTTA reverse primer 
 
• STAT4: 5’ GCCTCTATGGCCTGAC forward primer and 3’ 
CCAGCTCATCACCTCC reverse primer 
 
• Plastin 3 (PLS3) (T isoform): 5’ AGCTCCAGTTTGGCAGTTGT forward primer 
and 3’ CACTCTGGCTCCGATTCTTC reverse primer 
 
• TNFSF10 (TRAIL): 5’ ACGTGTACTTTACCAACGA forward primer and 3’ 
ATGCCCACTCCTTGAT reverse primer 
 
• ABCB4 (MDR2): 5’ AGCCAAAGCTGCCAACATACA forward primer and 3’ 
GCTCGGGCAATAGCAATCC reverse primer 
 
• GAPDH (housekeeping gene): 5’ GTGAAGGTCGGAGTCAACG forward 
primer and 3’ TGAGGTCAATGAAGGGGT C reverse primer 
 
Controls with no cDNA templates were performed to rule out contamination. The 
PCR reactions were carried out in the Applied Biosystems 7900HT Fast Real-Time PCR 
System with cycle parameters of 50°C for 2 minutes; 95°C for 10 minutes; and 40 cycles 
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of 95°C for 15 seconds and 60°C for 1 minute. This was followed by a dissociation stage 
of 95°C for 15 seconds, 60°C for 15 seconds and 95°C for 15 seconds. The Power Sybr® 
Green fluorescence intensity was measured at the end of each extension. The PCR 
product specificity was assessed by melting curve analysis and the quality of qRT-PCR 
was determined in two ways: the amplification efficiencies have to be 100 +/-10%, and 
correlation coefficients (r2) >95%. 
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CHAPTER 7: RESULTS AND DISCUSSION 
 
Samples collected from the Sezary Syndrome Patient and Healthy Control Donor 
 The CPT and PAX samples that were collected from a SS patient treated with 
Romidepsin (ID: 4510) are presented in Table 4. At week 2 of monthly cycle 4 and week 
3 of monthly cycle 6, the patient did not receive treatment and as such, no samples were 
collected at these time-points.  
 In addition, the CPT and PAX samples collected from the Healthy Control Donor 
(ID: 31) are presented in Table 5.  
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Table 4: Samples collected from the Sezary Syndrome patient 
Monthly 
Cycle 
Week Time Sample Collected: Pre- 
or Post-Romidespin 
Treatment 
Sample Type Collected 
Pre- and Post-
Romidepsin Treatment 
Baseline - Not applicable – no treatment 
administered 
Baseline CPT (no 
treatment) 
1 1 Pre and Post CPT 
1 2 Pre and Post CPT and PAX 
1 3 Pre and Post CPT 
2 1 Pre and Post CPT 
2 2 Pre and Post CPT and PAX 
2 3 Pre and Post CPT 
3 1 Pre and Post CPT 
3 2 Pre and Post CPT and PAX 
3 3 Pre and Post CPT 
4 1 Pre and Post CPT 
4 2 No Samples Collected No Samples Collected 
4 3 Pre and Post CPT and PAX 
5 1 Pre and Post CPT 
5 2 Pre and Post CPT and PAX 
5 3 Pre and Post CPT 
6 1 Pre and Post CPT 
6 2 Pre and Post CPT and PAX 
6 3 No Samples Collected No Samples Collected 
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Table 5: Samples collected from the healthy control donor 
Monthly 
Cycle 
Week Time Sample Collected: 
Morning (AM) or 
Afternoon (PM) 
Sample Type Collected In 
The Morning and 
Afternoon 
1 1 AM and PM CPT and PAX 
1 2 AM and PM CPT and PAX 
1 3 AM and PM CPT and PAX 
2 1 AM and PM CPT and PAX 
2 2 AM and PM CPT and PAX 
 
 
 
Comparison of Gene Expression Profiles in CPT Vacutainer and PAXgene Samples  
 
 Gene expression studies are an important tool to evaluate the genome-wide 
response of a disease to a particular treatment. In particular, this study utilized the 
Illumina microarray system to examine the differential gene expression profile in 
peripheral blood samples collected from a SS patient treated with Romidepsin over a 
period of 6 months. However, a critical step in microarray studies is the initial 
implementation of standardized blood collection and RNA isolation procedures to yield 
consistent gene expression results that occur in response to treatment, which can 
subsequently be used to predict responsiveness to treatment and to elucidate the 
underlying biological mechanisms.   
As such, gene expression profiles in blood samples simultaneously collected in 
both CPT and PAX tubes from the SS patient were first examined in order to compare the 
changes in gene expression between pre- and post-Romidepsin treatment samples as well 
as to examine the changes in gene expression across each month of the clinical trial as a 
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result of these 2 blood collection methods. This was performed to determine if the CPT 
and PAX blood collection methods identify similar or varying effects on gene expression.  
Gene expression data from microarray hybridizations from CPT and PAX samples 
collected from the SS patient at week 2 for monthly cycles 1-3, 5-6 and week 3 for 
monthly cycle 4 at both pre- and post-Romidepsin treatment timepoints were compared. 
These samples were used because both CPT and PAX samples were collected from the 
SS patient at only these timepoints. As shown in Table 4, PAX samples were collected at 
week 3 of cycle 4 because the SS patient did not receive treatment on week 2 of this 
monthly cycle. With a fold change cutoff of at least 1.5, a total of only 614 genes that 
changed in expression were different between pre- and post-Romidepsin treatment 
samples.  
 These genes were further analyzed using Principal Component Analysis (PCA) by 
plotting the covariance on axes in a multi-dimensional space to examine the variability in 
the gene expression within the dataset (Figure 15). 
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Figure 15: Principal Component Analysis of pre- and post-Romidepsin treatment CPT 
Vacutainer and PAXgene samples from the Sezary Syndrome Patient 
PCA of 614 changed genes were extracted with a fold change of at least 1.5 between pre- 
and post-Romidepsin treatment samples collected in CPT and PAXgene tubes at week 2 
for monthly cycles 1-3, 5-6 and week 3 for monthly cycle 4.  
Pre: pre-Romidepsin treatment; PST: post-Romidepsin treatment; cpt: CPT Vacutainer 
tubes; pax: PAXgene tube; c: cycle 
 
  
 
The first principal component, which accounted for both the first axis and most of 
the variability in the data by distinguishing genes based on their average overall 
expression, was equivalent to 50% of all the gene expression data. These results indicated 
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that the samples did not cluster together based on the tube type. Instead, CPT and PAX 
samples collected at the same time displayed similar gene expression profiles as 
evidenced by the grouping of CPT and PAX samples collected at either the pre- or post-
treatment time of each monthly cycle together. These results suggest that CPT and PAX 
samples could be utilized in the same microarray study to examine gene expression 
profiles. 
 Significant differences in gene expression were also detected at the end of each 4-
hour treatment with a shift in expression between the pre- and post-Romidepsin treatment 
samples at each monthly cycle. More specifically, all of the pre-treatment CPT and PAX 
samples at each monthly cycle grouped together and all of the post-treatment CPT and 
PAX samples grouped together.  
 Although some of the changes in gene expression were transitory, other changes 
in gene expression remained one month later as indicated by a shift in the expression 
profiles of the pre-treatment samples at months 2 through 6. These results suggested that 
the Romidepsin treatment induced an immediate effect on the gene expression profile, 
some of which were cumulative over the 6 monthly cycles. 
 
 
Identification of Genes Uniquely Detected In CPT Vacutainer Samples and PAXgene 
Samples 
 
 Overall, although CPT and PAX samples had similar gene expression profiles 
across the 6 monthly cycles, these samples were then compared in order to identify the 
functional categories of genes that were uniquely detected by each blood collection 
method. The pre- and post-Romidepsin treatment CPT and PAX samples simultaneously 
collected from the SS patient were again used for this analysis.  
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 Paired t-tests were performed and genes were considered significant with a p-
value <0.05 and a fold change >2. Out of the total 18,190 genes detected on the Illumina 
beadchip, 13,277 were common to both CPT and PAX samples, which indicated that 
most of the immune cell specific genes were expressed in RNA from both CPT and PAX 
samples. The results for PAX samples yielded 625 uniquely detected genes with an 
expression 2 fold or more compared to CPT samples, as well as 205 uniquely detected 
genes in CPT samples with an expression 2 fold or more compared to PAX samples.  As 
expected in the PAX samples, many of the uniquely detected genes were red blood cell 
specific genes or genes expressed in granulocytes.  
 These gene lists were then further analyzed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) in order to condense the gene lists into 
groups based on gene function (62). The functional categories of up-regulated genes that 
were uniquely detected in CPT samples are listed in Table 6, and those uniquely detected 
in PAX samples are listed in Table 7. Enrichment refers to the mean of the p-values (in 
minus log scale) and is a measure of the size of an annotation cluster with reference to the 
total number of genes in the list and the relative ranks of the members of the annotation 
cluster. In addition, sensitivity refers to the ratio of genes detected in the CPT or PAX 
samples for a specific function relative to the total number of genes on the Illumina 
beadchip that were related to the same function. The False Discovery Rate (FDR) 
represents the expected false positive rate. 
 Table 6 indicates that CPT samples significantly detected mitochondrial and 
protein biosynthesis related genes, in addition to genes related to acetylation. These 
results suggested that the Romidepsin treatment resulted in hyperacetylation that in turn 
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promoted the transcription of genes related to growth arrest, differentiation, and apoptosis 
with subsequent protein translation. In addition, genes related to a deficiency of 
mitochondrial complex I were detected with a sensitivity of 50%. The mitochondrial 
complex I is one of four complexes in the respiratory chain that enables the entry of 
electrons via the oxidation of NADH, with ATP production being the end-product of the 
chain. In addition, several proteins, including apoptosis inducing factor (AIF) are 
involved in the assembly of the complex. Research has shown the reduced expression 
levels of AIF owing to a mitochondrial complex I deficiency are associated with 
increased production of superoxide radicals (63-64). In vitro research has also shown that 
this over-production of superoxide radicals triggers kinase activation that leads to the 
release of pro-apoptotic factors which culminates in cell death (65).  As such, the 
expression of mitochondrial related genes in the CPT samples suggested that the 
mitochondria-dependent apoptotic pathway was involved in Romidepsin mediated 
apoptosis in Sezary Syndrome.  
However, the PAXgene blood collection method resulted in the detection of more 
globin and erythrocyte genes along with interleukin 1 receptors and immunoglobulins 
(Table 7).  As stated, PAXgene derived RNA has been associated with high levels of 
contamination from alpha and beta globin transcripts which accounts for the detection of 
these genes with high sensitivities in these samples. The detection of globin transcripts in 
the PAX samples is consistent with a key difference in the CPT and PAX protocols 
where the CPT protocol involves the removal of erythrocytes and the purification of the 
PBMC layer but the PAX protocol does not remove the contaminating erythrocytes from 
the leukocyte population.  
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 As such, the detection of uniquely expressed genes in the CPT and PAX samples 
indicated that the peripheral blood RNA isolation method can affect the outcome of 
microarray gene expression studies. This, in turn, may positively or negatively impact the 
identification of differentially expressed genes related to response to Romidepsin 
treatment in the SS patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 
Table 6: Functional categories of up-regulated genes detected with >2 fold changes in 
CPT Vacutainer samples compared to PAXgene samples 
Functional Category Enrichment Sensitivity False 
Discovery 
Rate  
Mitochondrial complex I deficiency 56.82 3/6 (50%) 1.70% 
SM00739:KOW 50.66 3/8 (37%) 2.10% 
SM00651:Sm 39.73 5/17 (29%) 0.01% 
Ribosome 27.34 21/62 (33%) <0.01% 
IPR006649:Like-Sm ribonucleoprotein, 
eukaryotic and archaea-type, core 
25.21 5/17 (29%) 0.10% 
IPR001163:Like-Sm ribonucleoprotein 22.56 5/19 (26%) 0.10% 
Mitochondrial inner membrane 20.18 4/16 (25%) 1.40% 
Oxidative phosphorylation 19.37 6/25 (24%) 0.02% 
Respiratory chain 18.35 5/22 (22%) 0.20% 
Ribosomal protein 17.67 37/169 
(21%) 
<0.01% 
Ribonucleoprotein 14.92 44/238 
(18%) 
<0.01% 
Ubiquinone 14.49 7/39 (17%) 0.01% 
Membrane-associated complex 13.45 4/24 (16%) 4.80% 
Protein biosynthesis 12.92 28/175 
(16%) 
<0.01% 
Electron transfer 8.59 5/47 (10%) 4.10% 
Spliceosome 5 7/113 (6%) 4.30% 
mrna splicing 4.25 9/171 (5%) 2% 
Mitochondrion 4.24 34/647 (5%) <0.01% 
Acetylation 4.01 29/584 (4%) <0.01% 
Transit peptide 3.28 16/394 (4%) 0.20% 
Rna-binding 2.78 15/435 (3%) 1.60% 
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Table 7: Functional categories of up-regulated genes detected with >2 fold changes in 
PAXgene samples compared to CPT Vacutainer samples 
Functional category Enrichment Sensitivity False 
Discovery 
Rate 
Oxygen carrier 27.71 7/7 (100%) <0.01% 
IPR002337:Haemoglobin, beta 27.02 4/4 (100%) 0.40% 
PIRSF500045:hemoglobin, vertebrate 23.5 7/7 (100%) <0.01% 
Blood 21.55 7/9 (77%) <0.01% 
Oxygen transport 19.4 7/10 (70%) <0.01% 
IPR012292:Globin 18.91 7/10 (70%) <0.01% 
IPR000971:Globin, subset 18.91 7/10 (70%) <0.01% 
PIRSF036518:globin 16.45 7/10 (70%) <0.01% 
IPR004074:Interleukin-1 receptor, type 
I and type II 
15.44 4/7 (57%) 3% 
Erythrocyte 14.67 9/17 (52%) <0.01% 
IPR004075:Interleukin-1 receptor, type 
I/Toll precursor 
11.82 7/16 (43%) 0.03% 
IPR000157:Toll-Interleukin receptor 9.4 8/23 (34%) 0.03% 
Blood group antigen 8.53 8/26 (30%) 0.04% 
Cytokine receptor 8.15 5/17 (29%) 4.20% 
Heterotetramer 6.52 8/34 (23%) 0.30% 
IPR013106:Immunoglobulin V-set 3.54 19/145 (13%) 0.01% 
Metalloprotein 3 13/120 (10%) 2% 
Proto-oncogene 2.72 21/214 (9%) 0.20% 
IPR003599:Immunoglobulin subtype 2.49 27/293 (9%) 0.10% 
Immunoglobulin domain 2.12 29/379 (7%) 0.40% 
Transmembrane protein 2.04 45/611 (7%) 0.02% 
IPR013783:Immunoglobulin-like fold 2.03 31/412 (7%) 0.60% 
IPR007110:Immunoglobulin-like 2.01 28/377 (7%) 1.60% 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
Cell Types Related to Uniquely Detected Genes in CPT Vacutainer and PAXgene 
Samples 
  
 The genes that were uniquely detected in both CPT and PAX samples collected 
from the SS patient were then further analyzed to determine the specific cell types in 
which these genes were expressed. For this analysis, the uniquely detected genes from the 
CPT and PAX samples were cross-referenced to a list referred to as Immune Response in 
Silico (IRIS) genes (66). These are 1,688 immune cell specific genes that have been 
identified by previous functional and microarray studies, which are markers of various 
immune cell types. Genes that are highly expressed in a specific cell type are assigned to 
either of the categories: T-cells, B-cells, dendritic cells, NK cells, neutrophils or 
monocytes. However, genes that are specific to more than one cell type within a lineage 
are assigned to either the myeloid or lymphoid categories. 
Of the total 18,190 genes detected on the Illumina beadchip, a total of 727 were 
present on the IRIS list with 558 genes common to both CPT and PAX samples with just 
9 uniquely detected CPT genes and 110 uniquely detected PAX genes (Table 8). 
Furthermore, genes that were uniquely detected by the PAX blood collection method 
were significantly associated with neutrophils, which were not captured in the PBMC 
samples, as well as myeloid and monocyte cells. Genes that were uniquely detected by 
the CPT method were significantly associated with lymphoid cells and were expressed at 
low levels. The overall similarities between the 2 collection systems for the IRIS genes 
are shown in Table 8.  
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Table 8: Number of genes for each cell type that are represented among all genes and 
CPT and PAX specific genes 
Significant overrepresentations are indicated with stars. * p-value<0.1, ** p-value<0.01, 
*** p-value<0.0001 as determined by Fisher Exact Test 
Cell Type 
Number of 
immune cell 
specific genes 
on Illumina 
Beadchip that 
were identified 
on IRIS list 
Common CPT 
and 
PAX genes 
identified on 
IRIS list 
CPT specific 
genes 
identified on 
IRIS list 
PAX specific 
genes 
identified on 
IRIS list 
T Cell 63 60 0 0 
Neutrophil 34 4 0 29*** 
NK Cell 14 12 1 0 
Myeloid 260 172 2 74*** 
Monocyte 62 43 1 5* 
Lymphoid 170 156 4* 1 
Dendritic 
Cell 55 47 0 0 
B Cell 69 64 1 1 
Total 
number of 
identified 
genes on 
IRIS list  
727  
(out of a total of 
18,190 genes 
detected on the 
Illumina 
beadchip) 
 
 
558  
(out of a total of 
13.277 common 
CPT and PAX 
genes detected on 
the Illumina 
beadchip) 
 
 
9  
(out of a total of 
205 CPT 
specific genes 
detected on 
Illumina 
beadchip) 
 
 
110  
(out of a total 
of 625 PAX 
specific 
genes 
detected on 
Illumina 
beadchip) 
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Examination of CPT Vacutainer Samples for Accurate and Reproducible Microarray 
Results 
 
 The storage and handling of peripheral blood samples can significantly impact the 
data reproducibility in microarray studies. This is of particular importance in clinical 
settings that lack the equipment and/or trained personnel to process these samples and 
therefore require that the samples must be transported to distant sites for processing. 
 As mentioned, the samples in this study were collected at the Hospital of the 
University of Pennsylvania and then taken to the Wistar Institute for processing in a 
timely manner. In one case, the post-Romidepsin treatment sample from the SS patient 
collected in the CPT tube at week 1 of monthly cycle 2 was not taken to the Wistar 
Institute for processing immediately after collection from the patient. Instead, the sample 
was stored overnight at 4oC, transferred to Wistar the following morning and then 
processed for the isolation of PBMCs. To determine the effect of the delay in processing 
on the gene expression in this sample, the following analysis was carried out. 
 Principal Component Analysis was performed on the 614 genes that changed in 
expression (fold change >1.5, p-value <0.04) from the pre- and post-Romidepsin 
treatment samples collected only in the CPT tubes from the SS patient over the 6 monthly 
cycles. The results in Figure 16 showed that after each treatment at monthly cycles 1 to 6 
there was a progressive shift in the direction of second principal component indicating 
that the Romidepsin treatment progressively altered the expression of these genes so that 
samples collected during early treatments were located at the lower right quadrant and 
those collected at later timepoints moved progressively to the upper right quadrant. 
However, in the case of the month 2 post-treatment CPT sample that was refrigerated and 
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then processed the following day, this sample clustered with samples from months 5 and 
6 rather than months 1 and 2. 
 These results therefore indicated that the storage and handling conditions of CPT 
samples prior to RNA extraction can critically affect the gene expression results in 
microarray studies resulting in inaccurate results that do not reflect the expression of the 
genes in the cells of interest at the time of sample collection.  
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Figure 16: Principal Component Analysis of pre- and post-Romidepsin treatment CPT 
Vacutainer Samples from the Sezary Syndrome Patient 
PCA of 614 changed genes extracted with a fold change of at least 1.5 from samples 
collected in CPT tubes both pre- and post-Romidepsin treatment over 6 monthly cycles 
Note: cX.Y = monthly cycle X.week Y 
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Romidepsin Induced Gene Expression Profiles in CPT Vacutainer PBMC Samples  
Global gene expression analysis was also performed to specifically identify genes 
that were altered in the SS patient owing to the treatment with Romidepsin. For this and 
later analyses, focus was directed to pre-Romidepsin treatment CPT samples. More 
specifically, the samples analyzed were collected from the SS patient across the 6 
monthly cycles at the week 2 timepoint for cycles 1-3, 5-6 and the week 3 timepoint for 
cycle 4, as week 2 CPT samples were not collected in cycle 4. In addition, the expression 
of genes in these samples were compared to that in the CPT samples collected from a 
healthy control donor at all morning (AM) timepoints to account for changes that may be 
a reflection of circadian rhythms.  
Several informative genes were extracted that have been identified in previous 
studies to be diagnostic biomarkers for Sezary Syndrome such as GATA3, STAT4, PLS3, 
CDO1 and DNM3 (17, 67-68). These genes are differentially expressed in the malignant 
CD4+ T-cells and the effect of the Romidepsin treatment on their expression may predict 
the clinical response in the SS patient.  
The ratio of maximum over minimum gene expression was calculated for each 
gene using only samples collected at monthly cycles 1 and 2 from both the SS patient and 
healthy control donor. Only monthly cycles 1 and 2 were used because these were the 
only cycles where matching samples were collected from both the SS patient and healthy 
control donor.  
A comparison of the number of genes whose expression levels were changed in 
the pre-Romidepsin treatment samples collected from the SS patient and the AM samples 
collected from the healthy control donor from monthly cycles 1 and 2 was then 
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performed. These analyses were carried out in order to determine whether the changes in 
gene expression observed in the SS patient were a result of the Romidepsin treatment or 
naturally occurring changes due to circadian. Figure 17 shows the number of informative 
genes, from monthly cycles 1 and 2 that were above background for the SS patient and 
healthy control donor across a range of fold changes. 
In order to focus on genes with more significant changes in response to therapy, a 
fold change cutoff of 2 was selected to further filter the informative genes. A comparison 
of the genes that changed in expression in the healthy control versus the SS patient over 
monthly treatment cycles 1 and 2 was performed. While only 62 genes were found to be 
differentially expressed over the 2 month period in the control donor, 632 genes were 
differentially expressed in the SS patient. This indicated that only 9.8% of the genes that 
changed in expression in the SS patient were a result of natural variation and not an effect 
of the Romidepsin treatment.  
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Figure 17: Comparison of the number of genes that changed in expression over monthly 
cycles 1 and 2 in the Sezary Syndrome patient and Healthy Control donor 
The number of changed genes above background level for the SS patient and Healthy 
Control donor from monthly cycles 1 and 2 were compared across a range of fold 
changes of 1.5 to 3. Samples used in this analysis were the pre-Romidepsin treatment 
CPT samples from the SS patient and the AM CPT samples from the healthy control 
donor.  
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In addition, the number of changed genes above background in the pre-
Romidepsin treatment CPT samples from only the SS patient for week 2 of monthly 
cycles 1-3, 5-6 and week 3 of cycle 4 was determined. The changes in the gene 
expression profile over the entire 6 month period in the SS patient are shown in Figure 
18. Using the cutoff value of 2 fold changes, a total of 3163 genes that changed in 
expression were extracted from these 6 samples over the 6 month treatment period. These 
3163 genes were the final list used for further analysis in this project. The top 20 of these 
genes based on fold change are presented in Table 9. The Romidepsin treatment in the SS 
patient modulated the expression of several of these genes that were related to cell 
proliferation, apoptosis and an immune response.  
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Figure 18: Number of genes that changed in expression in the Sezary Syndrome patient 
over 6 monthly cycles 
The number of changed genes above background level for the SS patient from the pre-
Romidepsin treatment CPT samples collected at week 2 of monthly cycles 1-3, 5-6 and 
week 3 of cycle 4 was determined across a range of fold changes of 1.5 to 3. 
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Table 9: Top 20 informative genes out of 3613 changed genes from monthly cycles 1 and 
2 in pre-Romidepsin treatment CPT Vacutainer samples 
Max- or Min/cycle 1 Fold Change: Ratio of maximum to minimum fold change ratio with 
respect to cycle 1 expression (+ up-regulated gene; - down-regulated gene) 
Ratio: Maximum/Minimum expression 
No Accession # Name Max or Min 
/ cycle 1 
Fold 
Change  
Ratio 
1 NM_000584 Interleukin 8 (IL8) 23.16 33.40 
2 NM_005217 Defensin, alpha 3, neutrophil-specific 
(DEFA3) 
30.66 30.66 
3 NM_004084 Defensin, alpha 1 (DEFA1) 25.97 25.97 
4 NM_021034 Interferon induced transmembrane 
protein 3 (IFITM3) 
25.77 25.77 
5 NM_001549 Interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3) 
22.00 22.00 
6 NM_005623 Chemokine ligand 8 (CCL8) 20.08 20.78 
7 NM_002823 Prothymosin, alpha (PTMA) -20.59 20.59 
8 NM_001548 Interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1) 
20.22 20.22 
9 NM_001781 CD69 molecule (CD69) -20.12 20.12 
10 NM_012483 Granulysin (GNLY) 18.18 18.18 
11 NM_006732 FBJ murine osteosarcoma viral 
oncogene homolog B (FOSB) 
-5.30 17.83 
12 NM_001549 Interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3) 
17.64 17.64 
13 NM_004867 Integral membrane protein 2A 
(ITM2A) 
-17.37 17.37 
14 NM_001547 Interferon-induced protein with 
tetratricopeptide repeats 2 (IFIT2) 
16.21 16.21 
15 NM_002983 Chemokine ligand 3 (CCL3) 10.53 14.55 
16 NM_004768 Splicing factor, arginine/serine-rich 11 
(SFRS11) 
-14.11 14.11 
17 NM_003430 Zinc finger protein 91 (ZNF91) -14.03 14.03 
18 NM_003880 WNT1 inducible signaling pathway 
protein 3 (WISP3) 
-13.10 13.10 
19 NM_001003 Ribosomal protein, large, P1 (RPLP1) -13.04 13.04 
20 NM_001565 Chemokine ligand 10 (CXCL10) 12.90 12.90 
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The expression of interleukin-8 (IL-8), a chemokine involved in the activation of 
immune cells during inflammation (69), was up-regulated over the 6 cycles of treatment.  
Previous research has shown that IL-8 is up-regulated in the epidermis of CTCL patients 
and may function as a pro-inflammatory mediator of the immune response that 
contributes to the pathogenesis of the disease (70). In addition, IL-8 is a Romidepsin 
sensitive gene as its’ expression level is consistently up-regulated in tumor cells treated 
with the HDACi (71). Moreover, the expression of IL-8 is up-regulated in other cancer 
types, such as breast cancer cells treated with another HDACi known as TSA (72). The 
pro-inflammatory chemokine IL-8 may therefore contribute to the tumor phenotype in 
CTCL. Since treatment with Romidepsin further induced IL-8, it may also have adverse 
effects by maintaining the aberrant expression of this gene. 
In addition to IL-8 being up-regulated, alpha defensins 1 and 3 (DEFA1 and 
DEFA3) were both up-regulated over the 6 cycles of treatment and research has shown 
that IL-8 stimulates neutrophils to release DEFA1 that functions as a chemoattractant for 
T-lymphocytes to drive an immune response (73). Thus, alpha defensins are cytotoxic 
peptides that have restricted expression in neutrophils and some lymphocytes and are 
involved in killing microbial pathogens, but also function as chemoattractants and 
activators of immune cells (74). Alpha defensins are tumor biomarkers and DEFA3 is a 
CTCL biomarker in CD4+ and CD4- lymphocytes (75). Elevated levels of alpha defensins 
have a cytotoxic effect against tumor cells (76) and are correlated with necrosis in cells 
adjacent to tumor cells (77). Therefore, elevated expression levels of alpha defensins as a 
result of the Romidepsin treatment may inhibit tumor proliferation in the SS patient.  
 61 
 
Although there was no significant increase in interferon gene transcription 
detected, several interferon-induced proteins with tetratricopeptide repeats genes were 
shown to be up-regulated in these samples (IFIT1, IFIT2, IFIT3). The IFITs are proteins 
that are rapidly synthesized in the presence of type I and type II interferons, which are 
primarily regulated post-transcriptionally. Type 1 and Type 2 interferons are pleiotropic 
cytokines that promote cellular resistance to viral infection and tumor proliferation. 
Previous in vitro research has shown that the elevation of IFIT1 which interacts with 
eukaryotic elongation factor-1A (eEF1A) results in apoptosis (78). In addition, IFITM3 
which encodes interferon induced transmembrane protein 3, was also up-regulated over 
the 6 cycles of treatment. The expression of IFITM3 is down-regulated in human breast 
cancer cells but highly expressed in normal or benign cells. In a rat model system,  the 
expression of IFITM3 significantly reduced the expression of osteopontin (OPN), an 
extracellular matrix glycophosphoprotein that is involved in malignant cell 
transformations (79). As such, the increased expression of IFITM3 as a result of 
Romidepsin treatment may reverse the malignant phenotype by promoting cell 
differentiation and growth arrest (80).  
 CD69 is a transmembrane glycoprotein whose expression is induced very early 
after activation of cells of most hematopoietic lineages, including T and B lymphocytes, 
NK cells, neutrophils and eosinophils and is therefore associated with a Th1 cell 
differentiation phenotype (81). CD69 is also constitutively expressed on human 
monocytes, platelets and epidermal Langerhans cells. Gene expression results indicated 
that CD69 was down-regulated over the 6 cycles of treatment. Other in vivo research has 
shown that down-regulation of CD69 expression in mice results in an immune response 
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against tumor cells, which can be attributed to a partial reduction in the synthesis of 
transforming growth factor (TGB-β) and  a subsequent lowered production of pro-
inflammatory cytokines and chemokines (82). 
  
Biological Functions and Pathways Modulated by Romidepsin Treatment  
 
 Biological function and pathway analyses using Ingenuity Pathways Analysis 
(IPA) were performed in order to elucidate putative gene expression associations between 
the 3163 changed genes in the pre-Romidepsin treatment CPT samples. Five networks 
were modulated by the Romidepsin treatment in the SS patient in that they included the 
greatest number of differentially expressed genes. These networks were: 
1. Antibacterial response, inflammatory response, antigen presentation 
2. Carbohydrate metabolism, small molecule biochemistry, DNA replication, 
recombination and repair 
3.   DNA replication, recombination and repair, cancer, cellular compromise 
4. Gastrointestinal disease, genetic disorder, inflammatory disease 
5. Cellular growth and proliferation, cell cycle, cell death 
These genes were also analyzed for the biological functions and canonical pathways 
that were significant in the dataset. Figure 19 shows the top 10 functions modulated by 
the Romidepsin treatment in the pre-infusion CPT samples from the SS patient. In 
particular, 235 and 456 genes from the dataset were identified in functions related to an 
inflammatory response and cell death, respectively. Tumor cell death owing to treatment 
was also confirmed by the significant decrease in tumor cell counts and the decrease in 
expression of the PLS3 gene, which is expressed only in the malignant T-cells.  
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Figure 19: Top 10 functions that were modulated by Romidepsin treatment in the Sezary 
Syndrome patient using Ingenuity Pathways Analysis 
3163 changed genes from the pre-Romidepsin treatment CPT samples collected from the 
SS patient were analyzed using IPA to identify common functions between the genes. 
The p-value represents the probability that the genes in the dataset and the canonical 
pathway are associated by chance alone. The threshold represents a p-value of 0.05. 
 
 
 
 Figure 20 show the top 10 canonical pathways modulated by the Romidepsin 
treatment in the pre-infusion CPT samples from the SS patient. Some of the biological 
pathways identified were triggering receptor expressed on myeloid cells 1(TREM1) 
signaling; production of reactive oxygen species (ROS) in macrophages, and CD28 
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signaling in T-helper cells. TREM1 genes code for cell surface receptors expressed on 
neutrophils, monocytes and macrophages and the signaling pathway involves the 
activation of these myeloid cells with the subsequent production of inflammatory 
cytokines, chemokines, ROS and phagocytosis (83). As such, TREM1 signaling results in 
the production of proinflammatory cytokines such as IL-8, which was up-regulated in 
these samples. In addition, the pathway involving the production of ROS by macrophages 
results in tumor suppression via Fas-mediated apoptosis (84) and the CD28 signaling 
pathway in T-helper cells results in T-cell activation that leads to the production of IL2, 
which is a Th1 cytokine.  
Other pathways that are involved in promoting an immune response were also 
found to be activated, including various molecular pathways implicated in an induction of 
tumor cell apoptosis and cellular differentiation. 
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Figure 20: Top 10 Canonical Pathways that were modulated by Romidepsin treatment in 
the Sezary Syndrome patient using Ingenuity Pathways Analysis 
A total of 3163 changed genes from the pre-Romidepsin treatment CPT samples collected 
from the SS patient were analyzed using IPA to identify pathway associations between 
the genes. The p-value represented the probability that the genes in the dataset and the 
canonical pathway were associated by chance alone. The ratio represented the number of 
genes from the dataset that mapped to the pathway relative to the total number of 
molecules in that pathway. The threshold represented a p-value of 0.05. 
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Principal Component Analysis of Genes in CPT Vacutainer PBMC Samples 
 
 Principal Component Analysis (PCA) was also performed to examine the 
variability in the gene expression data from the pre-Romidepsin treatment CPT samples 
collected from the SS patient over the 6 monthly by examining the 3163 changed genes 
(Figure 21).  The first principal component, which accounted for most of the variability in 
the data, was equivalent to 67% of all the gene expression data.   
The gene expression profile shifted from left to right with monthly cycle 1 on the 
left and cycles 5 and 6 on the right along the long axis of the 1st principal component. 
This indicated that there was a cumulative effect from the Romidepsin treatment over the 
6 monthly cycles. Moreover, the shift from cycle 1 to 2 had the greatest effect suggesting 
that the SS patient exhibited a response to the Romidepsin treatment after only the first 
treatment cycle. In addition, a smaller effect on the first principal component was 
observed between cycles 2 and 3; cycles 3 and 4; and cycles 4 and 5 and therefore a 
continued response to the treatment occurred across these cycles. However, there was 
almost no effect on the first principal component at cycles 5 and 6, which indicated that 
at the end of the clinical trial the Romidepsin treatment was having a reduced impact at 
the gene expression level.  
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Figure 21: Principal Component Analysis of pre-Romidepsin treatment CPT Vacutainer 
Samples from the Sezary Syndome patient 
The first principal component accounted for 67% of the variation in 3163 changed genes 
in the SS patient over 6 monthly cycles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-100 -50 0 50 
-20 
-10 
0 
10 
20 
30 
cycle.1 
cycle.2 
cycle.3 
cycle.4 
cycle.5 
cycle.6 
Principal Component 1 (67%) 
Pr
in
ci
pa
l C
om
po
ne
nt
 2
 (1
1%
) 
 68 
 
Comparison of Expression Profiles of Specific Genes Identified as CTCL Biomarkers 
 
 The expression profiles of several genes identified in our previous studies as 
CTCL biomarkers were also examined and comparisons were performed between the SS 
patient and the healthy control donor (68). Figures 22 to 26 show the changes in gene 
expression profiles from the baseline timepoint (prior to any treatment) and over the 6 
monthly cycles of treatment for: 1) CTCL biomarkers GATA3, STAT4,  PLS3, and 
TRAIL,  and 2) the multi drug resistance 2 gene, MDR2, as a potential marker for the 
development of drug resistance.  
The expression profiles observed for GATA3 (Figure 22) and STAT4 (Figure 23) 
were consistent with previous research (67). GATA3, which is up-regulated in patients, 
promotes Th2 cell differentiation, which is characteristic of the disease, and inhibits Th1 
differentiation which would facilitate an anti-tumor response (85).  Over-expression of 
GATA3 therefore enables the progression of the malignant phenotype. The microarray 
results indicated that while GATA3 expression levels in the SS patient remained stable for 
the first 2 months, the Romidepsin treatment resulted in lowered expression levels of 
GATA3 at monthly cycles 3 and 4 with the expression remaining relatively constant 
through cycle 6 of treatment. This was consistent with the reduction in the numbers of 
GATA3 expressing malignant cells as the treatment progresses. However, these levels 
were still significantly higher across the 6 monthly cycles compared to the healthy 
control donor suggesting that the Romidepsin treatment may have resulted in a reduction 
in the malignant cells but there was still a Th2 environment present. 
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Figure 22: Gene Expression Profile of GATA3 
The expression profile of GATA3 before the start of the clinical trial (baseline, c.0) and 
over 6 monthly cycles in the SS patient from pre-Romidepsin treatment CPT samples 
shown on the left and the expression profile of GATA3 over 2 monthly cycles in the AM 
CPT samples from the Healthy Control donor on the right.  
SS = Sezary Syndrome Patient; HD = Healthy Donor; c = cycle; w = week; c0 = baseline 
sample (no treatment) collected before start of the clinical trial 
 
 
In contrast, STAT4, which promotes Th1 differentiation (86), was significantly 
down-regulated in the SS patient as compared to the healthy control donor. As the 
Romidepsin treatment progressed over the 6 cycles, there was only a slight and somewhat 
transient increase in STAT4 expression, although it was still 5 fold lower than in the 
control donor.  The expression of STAT4 is severely repressed in both normal CD4+ cells 
as well as in malignant cells (34), and these results suggested that the Romidepsin 
treatment did not significantly alter the low expression levels of STAT4 in the patient.  
Thus, the STAT 4 dependent Th1 response of these patients remained impaired. This was 
consistent with our observations that the GATA3 levels remained elevated even after 
treatment. 
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Figure 23: Gene Expression Profile of STAT4 
The expression profile of STAT4 before the start of the clinical trial (baseline, c.0) and 
over 6 monthly cycles in the SS patient from pre-Romidepsin treatment CPT samples 
shown on the left and the expression profile of STAT4 over 2 monthly cycles in the AM 
CPT samples from the Healthy Control donor on the right.  
SS = Sezary Syndrome Patient; HD = Healthy Donor; c = cycle; w = week; c0 = baseline 
sample (no treatment) collected before start of the clinical trial. 
 
 
 Plastin T (PLS3) is a member of the actin bundling protein family that is 
expressed in all tissues except in lymphoid cells, which normally express another family 
member, Plastin L (LCP1) (87). PLS3 is a single gene marker for CTCL in approximately 
75% of patients examined (67). In Figure 24, the levels of PLS3 expression shown for the 
healthy control donor were the background levels of expression detected on the 
microarray beadchip, as this gene is not expressed in healthy PBMC. However, PLS3 was 
significantly over-expressed in the SS patient. A similar aberrant expression of PLS3 in 
CTCL patients has been identified in earlier studies (67-68). In addition, PLS3 was highly 
over-expressed at the baseline timepoint and appears to increase slightly at cycle 1 of 
treatment. However, as the Romidepsin treatment progressed, there was a highly 
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significant decrease in the levels of the PLS3 message dropping to levels only slightly 
above background. This indicated that the Romidepsin treatment was effective in 
eliminating the malignant cells, as the loss of PLS3 expression in the SS patient was an 
indicator of the death of the tumor cells. Some residual expression of this gene remained 
at cycle 6 of treatment in the patient and might have indicated the presence of a class of 
Romidepsin resistant cells that remained. 
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Figure 24: Gene Expression Profile of PLS3 
The expression profile of PLS3 before the start of the clinical trial (baseline, c.0) and over 
6 monthly cycles in the SS patient from pre-Romidepsin treatment CPT samples shown 
on the left and the expression profile of PLS3 over 2 monthly cycles in the AM CPT 
samples from the Healthy Control donor on the right.  
SS = Sezary Syndrome Patient; HD = Healthy Donor; c = cycle; w = week; c0 = baseline  
Sample (no treatment) collected before start of the clinical trial 
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The expression level of the TRAIL gene, also known as tumor necrosis factor 
superfamily member 10 (TNFSF10), was over-expressed in the SS at the baseline 
timepoint as well as over cycles 1 to 5, with a further increase in expression at cycle 6 as 
compared to the healthy control donor (Figure 25). TRAIL is a member of the tumor 
necrosis factor (TNF) superfamily and functions to induce apoptosis in tumor cells. It is 
expressed in the normal as well as malignant T-cells. CTCL patients over-express TRAIL, 
and this may be a mechanism by which the malignant cells evade immune surveillance by 
targeting normal cells for apoptosis (67). In this study, the expression level of TRAIL 
progressively increased in the SS patient receiving treatment despite the clear indication 
that the tumor cell numbers were significantly reduced. This suggested that the increase 
in TRAIL expression was not associated with the tumor cells but rather the normal 
immune compartment.  
 
 
 
 
 
 73 
 
TRAIL
0
2000
4000
6000
8000
SS
c.0
SS
c.1
SS
c.2
SS
c.3
SS
c.4
SS
c.5
SS
c.6
HD
c.1.1
HD
c.1.2
HD
c.1.3
HD
c.2.1
HD
c.2.2
SS Patient/Healthy Donor Timepoint
E
xp
re
ss
io
n
 
Figure 25: Gene Expression Profile of TRAIL 
The expression profile of TRAIL before the start of the clinical trial (baseline, c.0) and 
over 6 monthly cycles in the SS patient from pre-Romidepsin treatment CPT samples 
shown on the left and the expression profile of TRAIL over 2 monthly cycles in the AM 
CPT samples from the Healthy Control donor on the right.  
SS = Sezary Syndrome Patient; HD = Healthy Donor; c = cycle; w = week; c0 = baseline 
sample (no treatment) collected before start of the clinical trial 
 
 
 
 In Figure 26, the MDR2 expression levels for both the SS patient and healthy 
donor were similar with an almost steady expression level across the monthly cycles. The 
MDR superfamily is a group of ATP-binding cassette (ABC) transporters that is involved 
in transporting various molecules across intra- and extra-cellular membranes. The two 
members of the of the human multi-drug resistant (MDR) (P-glycoprotein) family are 
MDR1 and MDR2. Several cancers have an acquired resistance to drugs in that the 
patient initially responds to treatment, but later develops a resistance to the drug. The 
MDR1 gene encodes for a protein product called Mdr1, which is an energy driven efflux 
transporter that maintains non-toxic concentrations of various chemotherapeutic drugs.  
 The occurrence of multidrug resistance in humans is usually correlated with the 
increased expression of MDR1 along with a decreased accumulation of the drug 
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intracellularly. Some previous studies utilizing various cancer cell lines indicate that 
chemoresistance to Romidepsin is a result of the drug inducing the over-expression of the 
MDR1 gene (88-89). However, recent research shows that following treatment with 
Romidepsin, CTCL patients exhibited low-level increased MDRI expression in PBMC 
samples as well as transient low-level MDRI increased expression in tumor biopsy 
samples (90). Since there was data in this study that not all of the malignant cells were 
eliminated following Romidepsin treatment, the effect of the treatment on the expression 
of MDR2, which has been shown to function primarily as a phosphatidylcholine 
translocator as well as a drug transporter, was also examined (91-92). The similar 
expression levels of MDR2 in the SS patient receiving treatment and the healthy control 
donor suggested that the expression of MDR2 was not impacted by Romidepsin treatment 
and did not correlate with resistance to the treatment. Other research has indicated that 
the inability of MDR2 to transport some drugs may be a result of the inability of the drug 
to stimulate ATPase and initiate transport, as well as reduced drug binding to the Mdr2 
protein product (93-94).  
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Figure 26: Gene Expression Profile of MDR2 
The expression profile of MDR2 before the start of the clinical trial (baseline, c.0) and 
over 6 monthly cycles in the SS patient from pre-Romidepsin treatment CPT samples 
shown on the left and the expression profile of MDR2 over 2 monthly cycles in the AM 
CPT samples from the Healthy Control donor on the right.  
SS = Sezary Syndrome Patient; HD = Healthy Donor; c = cycle; w = week; c0 = baseline 
sample (no treatment) collected before start of the clinical trial 
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Validation of Expression Profiles of Biomarkers for CTCL cells  in CPT and PAXgene 
samples by Quantitative Real Time Polymerase Chain Reaction 
 
 To validate the microarray results, gene expression in CPT and PAX samples 
were compared using quantitative real-time PCR analysis (qRT-PCR). Genes that were 
previously identified in other studies to have altered expression levels in CTCL patients 
were selected (GATA3, PLS3, STAT4, TRAIL) as well as the MDR2 gene.  
 The expression levels of these genes in the SS patient from pre- and post-
Romidepsin treatment samples collected in both CPT and PAX tubes at week 2 across the 
6 monthly cycles were normalized to the expression of the housekeeping gene GAPDH. 
CPT samples collected at cycle 6 were omitted from this analysis because of interference 
with the PCR of the RNA. In addition, CPT and PAX samples from cycle 4 were omitted 
from this analysis because they were not collected at week 2. 
As shown in Figures 27 to 31, comparisons of expression levels were performed 
between microarray and qRT-PCR results for CPT and PAX samples for these genes. 
Overall, the microarray and qRT-PCR data for all of the genes in the CPT and PAX 
samples were in concordance as evidenced by similar expression profiles from cycle 1 to 
6 for these two analysis methods. Thus, the gene expression trends determined from the 
Illumina microarray analysis were reproduced in the PCR results.   
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Figure 27: Validation of GATA3 microarray data by quantitative Real Time PCR 
Comparison of array and qRT-PCR GATA3 expression data for CPT Vacutainer and 
PAXgene samples from the SS patient across 6 cycles. 
Microarray = ARR; qRT-PCR = PCR; CPT Vacutainer = cpt; PAXgene = pax 
 
 
 78 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
cycle.1 cycle.2 cycle.3 cycle.5 cycle.6
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
STAT4 cpt-ARR
STAT4 pax-ARR
STAT4 cpt-PCR
STAT4 pax-PCR
 
Figure 28: Validation of STAT4 microarray data by quantitative Real Time PCR 
Comparison of array and qRT-PCR STAT4 expression data for CPT Vacutainer and 
PAXgene samples from the SS patient across 6 cycles. 
Microarray = ARR; qRT-PCR = PCR; CPT Vacutainer = cpt; PAXgene = pax 
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Figure 29: Validation of PLS3 microarray data by quantitative Real Time PCR 
Comparison of array and qRT-PCR PLS3 expression data for CPT Vacutainer and 
PAXgene samples from the SS patient across 6 cycles. 
Microarray = ARR; qRT-PCR = PCR; CPT Vacutainer = cpt; PAXgene = pax 
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Figure 30: Validation of TRAIL microarray data by quantitative Real Time PCR 
Comparison of array and qRT-PCR TRAIL expression data for CPT Vacutainer and 
PAXgene samples from the SS patient across 6 cycles. 
Microarray = ARR; qRT-PCR = PCR; CPT Vacutainer = cpt; PAXgene = pax 
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Figure 31: Validation of MDR2 microarray data by quantitative Real Time PCR 
Comparison of array and qRT-PCR MDR2 expression data for CPT Vacutainer and 
PAXgene samples from the SS patient across 6 cycles. 
Microarray = ARR; qRT-PCR = PCR; CPT Vacutainer = cpt; PAXgene = pax 
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CHAPTER 8: CONCLUSION 
 
Histone deacetylase inhibitors induce apoptosis in cancer cell lines and result in clinical 
and molecular changes in cancer patients. Gene expression studies using microarray 
analyses and qRT-PCR have been previously reported on various cancer cell lines that 
have been treated with Romidepsin. However, my study focused on examining gene 
expression profiles in peripheral blood samples from a Sezary Syndrome patient treated 
with a novel HDACi, Romidepsin, over 6 monthly cycles using a healthy control donor 
for comparison. This study utilized the Illumina microarray system to examine the gene 
expression profile of both pre- and post-Romidepsin treatment samples collected from the 
SS patient in two blood collection tubes: CPT Vacutainer and PAXgene tubes. This 
comparison was carried out to establish standardized methods for blood sample collection 
in clinical settings that would be relatively simple to apply, but would yield consistent 
and accurate detection of changes in gene expression. To address this aim, the expression 
profiles of samples collected using both blood collection platforms were compared in 
order to validate the PAXgene system for the collection of blood samples for gene 
expression studies. In addition, the response to Romidepsin treatment in a SS patient 
undergoing treatment in a Phase III clinical trial in these samples was assessed. The 
results indicated that both the method used for sample collection and the timing of RNA 
isolation can significantly affect gene expression profiles from tissues and, in particular, 
whole blood samples, which were of particular interest in these studies.  Developing and 
standardizing methods of collection is of particular importance in clinical trials where 
samples are frequently collected at multiple and frequently distant locations requiring 
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transfer to a different location for processing.  This delay in processing results in 
significant changes in gene expression that can confound the interpretation of gene 
expression studies   
 A major finding in this study indicated that samples simultaneously collected in 
CPT and PAXgene tubes clustered together based on the time of collection rather than the 
tube type, as long as the CPT samples were processed immediately after collection, while 
the PAXgene samples stored for several months retained the information present at the 
time of blood collection. This demonstrated that the PAXgene system can be utilized in 
studies that traditionally have utilized the CPT collection method. More importantly, 
results in this study indicated that gene expression results from samples collected in CPT 
tubes can be inaccurate if these samples were not immediately processed after collection. 
However, samples stored for several months in the PAXgene tube yielded reproducible 
gene expression results. This supports the use of the PAXgene system for collecting 
blood samples from patients to be analyzed for gene expression as these samples can be 
transported and stored for several months before being processed without degradation of 
the information present at the time of sample collection and produce microarray quality 
RNA.  
 In addition, although samples collected in CPT and PAXgene tubes yielded 
similar gene expression results, samples collected in both tube types expressed some 
unique genes and recovered genes from different cell types with varying sensitivities. 
However, the PAXgene system generates RNA from important cell types that were 
excluded from the CPT blood collection method, providing a more complete analysis of 
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gene expression in additional cell types that may be important for understanding disease 
states or, as in this study, responsiveness to therapy.  
 The results also showed that Romidepsin was an effective treatment option for 
Sezary Syndrome, as the treatment resulted in changes to the global gene expression in 
the patient, which was cumulative over the 6 months of the clinical trial. These changes 
were associated with the killing of the tumor cells as well as some apparent changes in 
the normal cells.  However, the results also suggested that not all of the tumor cells were 
eliminated, as low levels of PLS3 were still detected at the end of the 6 month trial. This 
was consistent with a diagnosis of recurrent SS in the patient 7 months after the end of 
the clinical trial when the Romidepsin treatment was terminated.  The inability to mount 
an effective Th1 response, as indicated by the fact that STAT4 level increases were quite 
marginal, suggests combination therapies with HDACi’s and biological response 
modifiers that can induce this response may be important. The results further validated 
earlier studies with cell lines that showed the expression of differentially expressed genes 
related to acetylation, cell differentiation and apoptosis following treatment with 
Romidepsin. Importantly, the findings in this study identified various biological pathways 
and functions of differentially expressed genes that may contribute to understanding the 
mechanism of the response observed in Sezary Syndrome patients treated with 
Romidepsin and may explain why only some patients are capable of responding to the 
treatment. 
 Several genes displayed altered expression patterns in the patient following 
treatment with Romidepsin that can be attributed to an enhanced clinical status. These 
included DEFA1, DEFA3, and a number of interferon induced genes including IFIT1, 
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IFIT2, IFIT3, IFITM3 as well as genes identified in earlier studies as CTCL biomarkers 
such as GATA3 and PLS3. In addition, this study validated the expression of STAT4 and 
TRAIL, whose expression was altered in patients diagnosed with Sezary Syndrome. 
Overall, these results supported the need for implementing standardized blood 
collection and RNA isolation protocols and showed that the PAXgene method was highly 
suitable for collecting peripheral blood samples for gene expression studies. However, 
although treatment with Romidepsin can be effective for improving the clinical outcome 
of a patient with Sezary Syndrome, the results of this study suggested that combination 
therapies that target various genes in diverse pathways may result in a more complete 
removal of malignant cells and more prolonged treatment responses. 
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